Background: Early b-lactamase inhibitors were combined with established penicillins, but different combinations may be more appropriate to counter current b-lactamase threats, with development facilitated by the US Generating Antibiotic Incentives Now (GAIN) Act. Cefepime/tazobactam is especially attractive, combining an AmpC-stable cephalosporin with a clinically established inhibitor, active against ESBLs and suitable for high-dose administration.
Introduction
The 1970s and early 1980s saw two strategies to overcome acquired penicillinases, then already prevalent in Gram-negative bacteria. Many companies developed 'b-lactamase-stable' oxyimino-cephalosporins, whilst a few developed b-lactamase inhibitors to protect existing penicillins. Both approaches achieved some success, though resistance accumulated over time. By the late 1980s, ESBLs were already eroding oxyimino-cephalosporin utility, and have since proliferated greatly. 1 Meanwhile, the penicillins used in inhibitor combinations (particularly amoxicillin and ticarcillin) proved challenging to protect owing to their extreme lability, and resistance is frequent in bacteria that have multiple or copious b-lactamases. 2 It was quickly recognized that clavulanate and tazobactam could protect oxyimino-cephalosporins against ESBLs, with MICs often reduced far below those of the penicillins used in clinical combinations. This behaviour is exploited in ESBL detection tests 1 but not in clinical combinations. With (i) oxyimino-cephalosporin and inhibitor patents owned by different companies and eroding in parallel and (ii) the general challenges of antibacterial development and commercialization, 3 there was little scope or business incentive for development of combinations of soon-to-be-generic agents. Moreover, most prospective cephalosporin/inhibitor combinations failed to cover bacteria with hyperproduced AmpC enzymes, making them less attractive than carbapenems, which evade both AmpC and ESBL enzymes. Cefepime/inhibitor combinations were the obvious exception, given cefepime's stability to AmpC, 4 but cefepime's sponsors took the view that their molecule was adequately active against many ESBL strains at CLSI's then breakpoints (S 8, R .16 mg/L) and did not need protection with an inhibitor. The fact that this breakpoint was too high for the commonly used 1 g twice-daily regimen only gradually achieved acceptance, as clinical failures were reported against ESBL strains with MICs of 2-4 mg/L. 5 EUCAST 6 adopted S 1, R .4 mg/L breakpoints, and CLSI later lowered its susceptible breakpoint to 2, with MICs of 4-8 mg/L considered susceptible to higher and/or more frequent doses. 7 Another shift was that the TEM and SHV ESBLs, often conferring only modest rises in cefepime MICs, were supplanted by CTX-M-15, typically conferring substantial resistance. 8, 9 We previously showed that cefepime/clavulanate was widely active in vitro against Enterobacteriaceae with ESBLs and AmpC enzymes. 4 Subsequent interest has concentrated on cefepime/ tazobactam, based on tazobactam being more chemically stable than clavulanate, easier to manufacture, less likely to induce AmpC, 2 and better tolerated at high dosage (up to 2 g thrice daily, by 90 min infusion, for 7 days, in combination with equal amounts of cefepime). 10 Several cefepime/tazobactam combinations are marketed in India, 11 with positive case series described. 12 A trial in urinary tract infection, with or without concurrent genitourinary tract pathology, reported 93.3% clinical cure. 13 However, all these combinations retain an 8:1 cefepime:tazobactam ratio, as for piperacillin/ tazobactam, meaning that even the maximal 2!0.25 g thricedaily regimen delivers only 0.75 g tazobactam per day. This is low compared with 1.5 g exposure used in recently licensed ceftolozane/tazobactam, which uses a strongly antipseudomonal cephalosporin that lacks cefepime's stability to enterobacterial AmpC. 14 Legislation to encourage the repurposing and reformulating of old antibiotics, notably the US Generating Antimicrobial Incentives Now (GAIN) Act, may give commercial viability to the development of cefepime with high-dose tazobactam, and we explored the potential of this combination using panels of characterized organisms.
Materials and methods

Bacteria
Organisms (n " 593) were recent clinical submissions to the UK national reference laboratory (Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, AMRHAI, at PHE Colindale, London). Bacterial identification was by MALDI-TOF (Bruker Daltonics, Bremen, Germany), and carbapenemase genes (bla IMP , bla KPC , bla IMP , bla NDM , bla OXA-48-like , bla VIM ) were detected by PCR; 15 other mechanisms were inferred by interpretive reading of phenotypes. 16 The species distribution of Enterobacteriaceae isolates representing different resistance mechanisms is shown in Table 1 . None of these species is inherently resistant to cefepime or any comparator tested.
Susceptibility testing
MICs of cefepime were determined by CLSI agar dilution 17 with tazobactam at 0 and 4 mg/L; comparators were piperacillin with 4 mg/L tazobactam and ceftazidime (all Sigma-Aldrich, Poole, UK) and meropenem (Sequoia, Pangbourne, UK). MICs of cefepime with 8 mg/L tazobactam were determined for a subset of the isolates.
Given the differences in EUCAST and CLSI breakpoints for cefepime, and the lack of current guidance for cefepime/tazobactam, we reviewed data against a 'most conservative' breakpoint of cefepime/tazobactam 1!4 mg/L, predicated upon EUCAST's current 1 mg/L susceptibility breakpoint for unprotected cefepime and a 'most liberal' value of 8!4 mg/L based upon the upper bound of CLSI's 'dose-dependent susceptibility' ategory. 17 The ultimate breakpoint for any commercial cefepime/tazobactam formulation will depend on the dosage and upon pharmacodynamic analysis.
Results
Enterobacteriaceae
Irrespective of the presence of tazobactam, cefepime was universally active against control and penicillinase-producing Enterobacteriaceae at 1 mg/L; it was also active against 81.3% of the AmpC producers at 1 mg/L, rising to 100% at 8 mg/L ( Table 2) . Tazobactam, at 4 mg/L, expanded the proportion of AmpC hyperproducers susceptible at 1 mg/L to 96.7%, but did not cause major MIC reductions. In contrast, tazobactam greatly potentiated cefepime against ESBL producers: whereas only 20.5% of ESBL producers were susceptible to unprotected cefepime at 1 mg/L, 94.9% were susceptible to cefepime/tazobactam 1!4 mg/L; similarly, 54.5% of ESBL producers were inhibited by cefepime at 8 mg/L and 99.4% by cefepime/tazobactam 8!4 mg/L. MICs for Klebsiella oxytoca hyperproducing K1 enzyme were reduced one or two doubling dilutions by tazobactam, but largely remained in the 2-8 mg/L range.
All Enterobacteriaceae with NDM carbapenemases were resistant to cefepime/tazobactam 8!4 mg/L, as were 63% of those with KPC carbapenemases. The behaviours of isolates with VIM and The expansion of anti-Enterobacteriaceae activity was impressive compared with both piperacillin/tazobactam and ceftazidime, particularly against isolates that did not have carbapenemases. Based on the CLSI criterion of .16!4 mg/L, non-susceptibility to piperacillin/tazobactam was seen for 9/22 penicillinase-producers and 66/176 ESBL producers along with 71/91 AmpC producers and all the K. oxytoca hyperproducing K1 enzymes, whereas all these isolates, except for one ESBL producer, were susceptible to cefepime/tazobactam 8!4 mg/L. Ceftazidime non-susceptibility, based on CLSI's .2 mg/L criterion, was seen in .90% of isolates in most groups except (i) controls and penicillinase producers and (ii) K. oxytoca hyperproducing K1 b-lactamase. Meropenem was active at the CLSI susceptible breakpoints (S 1 mg/L) against all the ESBL producers, K1 isolates and AmpC producers as well as control strains and penicillinase producers. Neither cefepime/ tazobactam nor any of its comparators was widely active against carbapenemase producers. All these isolates were nonsusceptible to piperacillin/tazobactam, with ceftazidime susceptibility seen only for cefepime-susceptible isolates with OXA-48-like enzymes. In the case of meropenem, isolates with NDM enzymes were consistently resistant, whereas MICs for those with other enzyme types straddled breakpoints, with many OXA-48 isolates appearing meropenem susceptible at CLSI's S 1 mg/L criterion and with MICs of 2-8 mg/L for many with VIM metallo-enzymes.
Non-fermenters
Addition of tazobactam caused little or no shift in the MIC distribution of cefepime for: (i) Pseudomonas aeruginosa with normal or upregulated efflux; (ii) P. aeruginosa with MBLs, which were universally resistant; or (iii) Acinetobacter spp. with OXA carbapenemases. Tazobactam did cause downward shifts in the MIC distributions of cefepime for P. aeruginosa with VEB and PER ESBLs, Stenotrophomonas maltophilia and, more surprisingly, for Acinetobacter spp. with AmpC activity; only in the last of these cases, however, were cefepime MICs commonly shifted below 8 mg/L. Most cefepime-susceptible Acinetobacter spp. were directly inhibited by tazobactam at 4 mg/L.
In vitro dose-response effects
The effect of raising the tazobactam concentration to 8 mg/L rather than 4 mg/L, as routinely used, is illustrated for sub-sets of the Enterobacteriaceae isolates in Table 3 . Small additional downward shifts in MIC distributions, of around one doubling dilution, were seen for many b-lactamase-producing groups, including those with AmpC, ESBL KPC and K1 enzymes, though not for MBLproducing Enterobacteriaceae. MIC shifts for non-fermenter groups were minimal (not shown).
Discussion
Even at the most conservative likely breakpoint (1!4 mg/L), cefepime/tazobactam achieved good activity against Enterobacteriaceae with ESBLs and AmpC enzymes as well as those with acquired penicillinases. At 8!4 mg/L or 8!8 mg/L, corresponding to the upper edge of CLSI's 'dose-dependent susceptibility' category, 7 susceptibility was seen also for most cefepime-resistant isolates with K1, OXA-48 and VIM enzymes. Against non-fermenters, cefepime/tazobactam essentially retained cefepime's activity with only small further gains, notably against AmpC-producing Acinetobacter spp. This spectrum is impressive and exceeded that of unprotected cefepime, ceftazidime or piperacillin/tazobactam, more closely resembling the behaviour of meropenem.
Ceftolozane/tazobactam was not included here, but is an obvious comparison. The major difference between ceftolozane and cefepime, in relation to Enterobacteriaceae, is that ceftolozane is less stable to AmpC enzymes, which are poorly inhibited by tazobactam. Consequently, ceftolozane/tazobactam MICs for AmpC-derepressed Enterobacter spp. are mostly 4-8 mg/L, compared with 0.12-1 mg/L found for cefepime/tazobactam (Table 2) . 16, 19 ESBL producers too were more often susceptible to cefepime/tazobactam, though less strikingly so. Thus, among isolates collected in the BSAC Bacteraemia Surveillance from 2011 to 2015 (inclusive) 97.9% of ESBL Escherichia coli and 86.5% of ESBL K. pneumoniae were susceptible to ceftolozane/tazobactam at 1!4 mg/L (the FDA and EUCAST breakpoint) 16 compared, here, with 98.3% (59/60) ESBL E. coli and 92.4% (73/79) ESBL K. pneumoniae susceptible to cefepime/tazobactam 1!4 mg/L and all except one K. pneumoniae susceptible at 8!4 mg/L. The more consistent activity of cefepime/tazobactam against ESBL producers may relate to a shorter time above a concentration threshold being needed for tazobactam to protect cefepime than ceftolozane, at least for strains with CTX-M-15, which is the commonest ESBL. 20, 21 Easier protection of cefepime, in turn, may depend on the molecule's rapid permeation of Gram-negative bacteria and its low affinity for some enzyme types 22 and/or its greater affinity for PBP2, which may enhance cidality. 23 However, there is insufficient information on these aspects for ceftolozane to allow definitive conclusions and it is it unclear if the shorter time needed above threshold for tazobactam to protect cefepime is specific to CTX-M-15 or is generalizable to other ESBLs. Moreover, experience with piperacillin/ tazobactam shows significant unexplained variation in susceptibility among ESBL producers, even when these have the same b-lactamase(s) and belong to the same strain. 24 The frequent activity of cefepime/tazobactam against Enterobacteriaceae with VIM MBLs is surprising but mirrors behaviour AMRHAI sees with cefepime/clavulanate in reference testing Livermore et al. (the combination is tested to detect ESBLs in AmpC-inducible species but is also tested, gratuitously, against all Gram-negative submissions). As neither tazobactam nor clavulanate significantly inhibits metallo b-lactamases, 25 the likeliest explanation is that VIM enzymes themselves are only weakly active against cefepime and that resistance caused by co-produced ESBLs is substantially reversed by tazobactam or clavulanate. In the case of strains with OXA-48-like enzymes, MICs of cefepime/tazobactam for most cefepime-resistant isolates were reduced into the 2!4 to 8!4 mg/L range. This incomplete potentiation may seem surprising, given that cefepime, like ceftazidime, evades OXA-48-like enzymes, 18, 26 with any resistance arising from co-produced ESBLs, which should be inhibited by tazobactam. The behaviour may reflect isolates having multiple enzymes, permeability lesions or, speculatively, to OXA-48-like enzymes being able to inactivate tazobactam, as can KPC enzymes. 27 Ceftolozane/tazobactam MICs for ceftazidime-resistant OXA-48 producers referred to AMRHAI are mostly higher than found here for cefepime/tazobactam, exceeding 16!4 mg/L in just over 50% of cases. 16 These data again support the view that cefepime is an easier molecule to protect.
In summary, these data, along with a 7891 isolate survey of consecutive Gram-negative bacilli from international sources, 28 support the development of cefepime/tazobactam as a potential 'workhorse' combination, potentially supplanting piperacillin/tazobactam (the present workhorse) and achieving similar coverage to a carbapenem against ESBL and AmpC-producing Enterobacteriaceae. There was also some activity, at least at cefepime's 'dosedependent' breakpoints, against many strains with VIM and OXA-48-like carbapenemases. Whilst unlikely to be preferred definitive therapy where strains with these enzymes are implicated, the combination may have sufficient activity not to be a major selector of these carbapenemases.
Given the propensity of bacteria to acquire complex batteries of b-lactamases, often copiously expressed, it seems prudent to use the highest levels of tazobactam that can be safely dosed, and certainly more than in the 8:1 cefepime/tazobactam preparations Potential of cefepime/tazobactam JAC currently marketed in India. A 1:1 combination (WCK 4282) has been proposed by Wockhardt and, in a Phase I trial, was well tolerated at up to 2!2 g intravenous when given thrice daily, by 90 min infusion, for up to 7 days. 10 Comparison with published data suggests that cefepime/tazobactam should achieve a wider spectrum than ceftolozane/tazobactam against problem Enterobacteriaceae, whereas the advantage against P. aeruginosa lies with ceftolozane/tazobactam, based on ceftolozane being inherently more active than cefepime (or ceftazidime) against this species.
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